Low Libido

Eurycoma Longifolia as a potential adoptogen of male sexual health: a systematic review on clinical studies.

Thu HE, Mohamed IN, Hussain Z, Jayusman PA, Shuid AN · Chinese journal of natural medicines · 2017

Eurycoma longifolia (EL) has been well recognized as a booster of male sexual health. Over the past few decades, numerous in vivo animal studies and human clinical trials have been conducted across the globe to explore the promising role of EL in managing various male sexual disorders, which include erectile dysfunction, male infertility, low libido, and downregulated testosterone levels. The aim of the present review is to analyze and summarize the literature on human clinical trials which revealed the clinical significance and therapeutic feasibility of EL in improving male sexual health. This systematic review is focused on the following databases: Medline, Wiley Online Library, BioMed Central, Hindawi, Web of Knowledge, PubMed Central and Google Scholar, using search terms such as "Eurycoma longifolia", "EL", "Tongkat Ali", "male sexual health", "sexual infertility", "erectile dysfunction", "male libido", and "testosterone levels". Notably, only human clinical studies published bet

Menopause: diagnosis and management

NICE

This guideline covers diagnosing and managing menopause, including advice on managing symptoms such as low libido.

Qualitative Findings from a Pilot Trial of Mindfulness for Low Sexual Desire in Midlife and Older Women.

Thomas HN, de Cameron FA, Brotto LA, Thurston RC · Archives of sexual behavior · 2025

Low libido is a common and potentially distressing problem among midlife and older women. We recently reported results from a pilot randomized controlled trial of a mindfulness intervention for midlife and older cisgender women with low libido; the purpose of this qualitative investigation is to illustrate women's experiences with being recruited for, enrolling in, and participating in the trial. We conducted individual interviews with a subset of trial participants, some of whom attended a group-based mindfulness intervention and some attended an educational control group (N = 25). We also interviewed participants who were enrolled but did not attend any groups (N = 9). A semi-structured interview guide was developed by the study team. A co-investigator with qualitative research expertise and the primary investigator conducted interviews, which were audio recorded and transcribed. We used a thematic analysis approach to analysis, co-coding a subset of inter

Effects of distant biofield energy healing on adults associated with psychological and mental health-related symptoms: a randomized, placebo-controlled, double-blind study.

Trivedi MK, Branton A, Trivedi D, Mondal S, Jana S · Health psychology research · 2024 · n=39

In recent years, popularity of Biofield energy healing therapy has increased tremendously parallel to conventional therapy. However, due to insufficient scientific studies on biofield therapies, authors planned this clinical trial to examine the safety and effectiveness of biofield therapy in treating symptoms of psychological and mental health and to explore parameters for its effectiveness. One hundred fourteen participants (55 male, 59 female) underwent clinical trials. This trial was randomized, placebo-controlled, three parallel-groups, double-blind, and single-center with subjects who have one or more psychological and mental symptoms. Two sessions of distant (virtual) biofield energy attunement were given on days 0 and 90 for about 5 minutes to the subjects of biofield intervention group (n=39). Besides, control (n=35) and sham control (n=40) group subjects also received kind of treatment in a similar manner to nullify baseline responses. Subjects were assessed by psychological

Plantago ovata: Clinical study of overuse.

Agha RE, Saeed A, Nazar H · Pakistan journal of pharmaceutical sciences · 2016

The objective of the study was to undertake evidence-base study to evaluate clinical manifestation of the over-estimated use of herbal drug Plantago ovata and to compare it with placebo for the efficacy and adverse effects. The patients of both genders were included. Blood urea, creatinine, ALT, Serum B12, CP, ESR and liver function tests were performed. The data was statistically analyzed in both groups for differential symptomatology. In anorexia test verses control results showed that Plantago ovata husk and placebo showed the affected ratio as 81 percent and 50 percent, correspondingly. Whereas in clinical performance of heart burning, pain in epigastrium, low libido, body pain, dyspepsia, fever, burning sensation in palm and sole in test drug showed affected response as adverse effect 90%, 88% and as control drug, 36%, 29%, 22%, 25%, 38%, 30%, 33%, 57%, respectively. The results were highly marked in test drug i.e. in comparison with placebo. This is clearly evident from data anal

Patient-Reported Barriers to Sex Therapy for Men Referred by Their Urologist: A Pilot Study.

Dumbrava M, Jefferson F, Sischka M, Vencill J, Ziegelmann M, Britton C · Journal of sex & marital therapy · 2025 · n=23

Sex therapy is recommended for a range of male sexual dysfunction-including erectile dysfunction, ejaculatory disorders, and low libido-but utilization remains low even when men are referred by their urologist. Here we aimed to identify patient-reported barriers and facilitators to sex therapy attendance and predictors of both compliance and perceived benefit. Men referred to sex therapy by their urologist for sexual dysfunction were surveyed. The cohort comprised 106 cisgender males (median age 43), of whom 49% were commercially insured, and 52% had ≥1 psychiatric diagnosis, especially anxiety and mood disorders. Overall, 59% attended their initial consultation. Patients with psychiatric comorbidities were more likely to attend (p < 0.001), whereas commercially insured individuals were less likely than Medicaid recipients (p = 0.002). Of the 23 patients who completed a follow-up survey, 17 attended their consultation, and most (71%) found s

Prevalence, lifestyle, and risk factors of erectile dysfunction, premature ejaculation, and low libido in middle-aged men: first results of the Bavarian Men's Health-Study.

Herkommer K, Meissner VH, Dinkel A, Jahnen M, Schiele S, Kron M · Andrology · 2024

Erectile dysfunction (ED), premature ejaculation (PE), and low libido (LL) are reported as the most common male sexual dysfunctions. To evaluate the prevalence of ED, PE, and LL and associations with lifestyle risk factors and comorbidities in middle-aged men. This study included a population-based random sample of 2500 50-year-old men who completed validated questionnaires, including the International Index of Erectile Function, the Erection Hardness Score, the Sexual Complaints Screener, and further questionnaires. Multiple logistic regression of outcomes ED, PE, and LL was used to model the association with explanatory factors. The prevalence of at least one sexual dysfunction was 30%. 21%, 5.2%, and 7.2% of men had ED, PE, and LL, respectively. The risk of ED increased with PE (odds ratio [OR]: 1.94, 95% confidence interval [95%CI]: 1.22-3.08), LL (OR: 2.04, 95%CI: 1.26-3.29), higher waist circumference (OR: 2.23, 95%CI: 1.67-2.96), and lower urinary tract symptoms (LUTS) (OR: 1

Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms.

Sinclair J, Collett L, Abbott J, Pate DW, Sarris J, Armour M · PloS one · 2021 · n=10914

The use of cannabis for symptoms of endometriosis was investigated utilising retrospective archival data from Strainprint Technologies Ltd., a Canadian data technology company with a mobile phone application that tracks a range of data including dose, mode of administration, chemovar and their effects on various self-reported outcomes, including pelvic pain. A retrospective, electronic record-based cohort study of StrainprintTM users with self-reported endometriosis was conducted. Self-rated cannabis efficacy, defined as a function of initial and final symptom ratings, was investigated across the included symptom clusters of cramps, pelvic pain, gastrointestinal pain, nausea, depression, and low libido. Cannabis dosage form, dose and cannabinoid ratio information was also recorded. A total number of 252 participants identifying as suffering endometriosis recorded 16193 sessions using cannabis between April 2017 and February 2020. The most common method of ingestion was inhalation (n

Effect of housing conditions, management procedures and traits of the external male reproductive tract on the sexual behaviour of natural mating boars.

Hodel C, Nathues H, Grahofer A · Theriogenology · 2021

Although artificial insemination in pig production is widespread, many farms rely on natural mating (NM). For NM to be successful, adequate sexual behaviour and a sufficient libido level in boars is crucial for appropriate reproductive performance. Therefore, this observational study evaluated the libido level of 59 boars of different breeds used for NM by a scoring system ranging from 0 (no libido) to a maximum of 23 points (perfect libido) and analysed their general and andrological health as well as housing and management factors influencing the libido. The boars showed a mean libido score of 16.7 (SD ± 2.3). Crossbreed (median: 17.5, min: 14.0, max: 21.0) (p < 0.01) and Landrace (median: 17.5, min: 17.0, max: 21.0) (p < 0.05) boars showed significantly higher libido scores compared to Piétrain boars (median: 14.0, min: 13.0, max: 17.0). A non-slippery mating area was found to be positively associated with libido (p < 0.05),

Sexual Health

MedlinePlus

MedlinePlus, a service of the National Library of Medicine, offers comprehensive information on sexual health topics, including low libido, by compiling links to other reliable sources. It acts as a gateway to trusted health information.

Loss of libido

NHS

Official NHS information detailing common causes of low libido in both men and women, alongside advice on when to seek help and potential treatments.

Randomized, Placebo-controlled, Double-blind Study of Seven Coordinated Testosterone Treatment Trials in Older Men

n=790 · NCT00799617 · COMPLETED · COMPLETED

The Testosterone Trials are a multi-center set of trials involving 12 clinical sites geographically distributed across the United States. The primary specific aims are to test the hypotheses that testosterone treatment of elderly men whose serum testosterone concentrations are unequivocally low - and who have symptoms and objectively measured abnormalities in at least one of five areas that could be due to low testosterone (physical or sexual function, vitality, cognition, and anemia) - will result in more favorable changes in those abnormalities than placebo treatment. Two additional trials have been incorporated into the T Trial. Only men enrolled in the T Trial are eligible to participate in these trials. * The Cardiovascular Trial will examine if testosterone treatment results in more favorable changes in cardiovascular risk factors, compared to placebo. * The Bone Trial will test the hypothesis that testosterone treatment will increase volumetric trabecular bone mineral density (vBMD) of the lumbar spine as measured by quantitative computed tomography (QCT), compared with placebo treatment. A Pharmacokinetic (PK) Study is also being conducted within the context of the interventional T Trial. It will examine the variability of the serum testosterone (T) concentration after application of testosterone gel or placebo, four months after the start of treatment.

Phase 2 Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women

n=60 · NCT02215434 · COMPLETED · COMPLETED

Female sexual dysfunction (FSD) is an established side effect of Selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitors (SNRIs), causing symptoms such as loss of libido, arousal difficulties, or delayed orgasm or anorgasmia. Efficacy of testosterone therapy for the treatment of hypoactive sexual desire disorder (HSDD) in women has been demonstrated in studies including naturally and surgically menopausal women, either alone or in combination with estrogen, with or without progestin therapy.

Two Arm Open Label Pilot Study of Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy

n=23 · NCT02714049 · TERMINATED · TERMINATED

Unblinded study of flibanserin for 8 weeks with responders randomized 1:1 to receive study medication alone vs. study medication and sex therapy for 12 additional weeks.

Low libido in women

TRIP Database

The TRIP Database offers a search engine for clinical evidence, including research on low libido in women, aggregating guidelines, systematic reviews, and other evidence-based resources. It helps clinicians find high-quality information efficiently.

Male hypogonadism

TRIP Database

This search on the TRIP Database provides access to a wide range of evidence related to male hypogonadism, a condition often associated with low libido in men. It aggregates studies, guidelines, and reviews to support clinical decision-making.

Sexual dysfunction

Cochrane

Cochrane provides a collection of systematic reviews on various aspects of sexual dysfunction, which often includes or is related to low libido. These reviews rigorously assess the effectiveness of interventions.